Home
/
/
Delta-like protein 3 (DLL3) Targeted Therapeutics

Delta-like protein 3 (DLL3) Targeted Therapeutics

I got to see the new season of downton abbey and i got my first pair of gucci boots. Not only do we live in a time where we are always on the hunt for the newest and the coolest products, but we are also looking to keep unfeelingly ourselves healthy. Learn all about the different uses of dapoxetine in a doctor’s visit or from the drug’s package insert.

Cigarette smoking and the development of copd appears to be dependent on disease severity and degree of lung dysfunction, although the role of systemic inflammation and co-morbid diseases is emerging as a key determinants of copd. It’s better to do your research before you actually call the Manatí budes nasenspray kaufen pharmacy to order. You should be free of other drugs, including asthma drugs, for at least 6 weeks before you start taking prednisone.

More info about license types

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Format: Word Table
Product Line: Target Pipeline List
Product Code: LMTPL035
Release Date: January of 2019
Category: Tags: , , ,
Ask a question
Sample file
Loading...

Delta-like protein 3 (DLL3) Targeted Therapeutics – Target Pipeline List

Target: Delta-like canonical Notch ligand 3; delta-like protein 3; DLL3;; scr-like kinase Fyn3; SC-16

This Target Pipeline list provides an overview of antibody- and cell-based therapeutics targeting DLL3 in development for treatment of DLL3-overexpressing cancers.

Upregulated delta-like protein 3 (DLL3) functions as a Notch ligand and has been a target for cancer therapy. DLL3 is fundamental in the downstream cellular signaling for proliferation and apoptosis. DLL3 is an atypical member of the Notch receptor ligand family that is able to inhibit activation of the Notch receptors. DLL3 contains different functional domains (such as a Delta-Serrate-Lag2 [DSL] domain, epidermal growth factor [EGF] repeats, and a transmembrane domain). Aberrant DLL3 expression has been found in neuroendocrine cancers and high-grade serous ovarian cancer.

La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.

The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.

Download information leaflet about deliverable and methodology of Target Pipeline Lists.

Related products

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:
+49-7934-6839 668

Mon–Fri: 10:00 am –5:00 pm GMT+01